BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33983835)

  • 1. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
    Griffin JM; Rosenblum H; Maurer MS
    Circ Res; 2021 May; 128(10):1554-1575. PubMed ID: 33983835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
    Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
    Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the diagnosis and management of cardiac amyloidosis.
    Sher T; Gertz MA
    Future Cardiol; 2014 Jan; 10(1):131-46. PubMed ID: 24344669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates in Cardiac Amyloidosis Diagnosis and Treatment.
    Stern LK; Kittleson MM
    Curr Oncol Rep; 2021 Mar; 23(4):47. PubMed ID: 33725199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and treatment of cardiac amyloidosis.
    Gertz MA; Dispenzieri A; Sher T
    Nat Rev Cardiol; 2015 Feb; 12(2):91-102. PubMed ID: 25311231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Advances in the Management of Cardiac Amyloidosis.
    Vranian MN; Sperry BW; Valent J; Hanna M
    Curr Cardiol Rep; 2015 Nov; 17(11):100. PubMed ID: 26374453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
    Castaño A; Drachman BM; Judge D; Maurer MS
    Heart Fail Rev; 2015 Mar; 20(2):163-78. PubMed ID: 25408161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in the diagnosis and treatment of cardiac amyloidosis].
    Jurczyszyn A; Engel A; Rajzer M; Czepiel J; Mazurs G
    Przegl Lek; 2014; 71(6):340-5. PubMed ID: 25344976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misconceptions and Facts About Cardiac Amyloidosis.
    Nguyen FD; Rodriguez M; Krittanawong C; Witteles R; Lenihan DJ
    Am J Cardiol; 2021 Dec; 160():99-105. PubMed ID: 34610875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What should we know about cardiac amyloidosis? From clinical signs to treatment].
    Földeák D; Nemes A; Kalapos A; Domsik P; Kormányos Á; Krenács L; Bagdi E; Borbényi Z
    Orv Hetil; 2017 Nov; 158(46):1811-1818. PubMed ID: 29135289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Suspected cardiac amyloidosis - diagnostic steps for evaluation].
    Feldmann K; Hamm CW; Aßmus B
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1162-1168. PubMed ID: 32791553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.